share_log

ALLARITY THERAPEUTICS INC | 8-K: Current report

SEC announcement ·  Apr 5 08:33
Summary by Moomoo AI
On April 4, 2024, Allarity Therapeutics, Inc. announced a reverse stock split of its common stock, which will take effect at 9:30 a.m. Eastern Time on April 9, 2024. The reverse stock split, approved by the Board of Directors following authorization by stockholders at the 2024 Special Meeting, will consolidate every 20 shares of issued and outstanding common stock into one share. This move is intended to help the company regain compliance with Nasdaq's minimum bid price requirement. The company's common stock will trade on a split-adjusted basis from the market opening on April 9, 2024. No fractional shares will be issued; instead, stockholders will receive a rounded up whole share for any fractional share they would have received post-split. Adjustments will also be...Show More
On April 4, 2024, Allarity Therapeutics, Inc. announced a reverse stock split of its common stock, which will take effect at 9:30 a.m. Eastern Time on April 9, 2024. The reverse stock split, approved by the Board of Directors following authorization by stockholders at the 2024 Special Meeting, will consolidate every 20 shares of issued and outstanding common stock into one share. This move is intended to help the company regain compliance with Nasdaq's minimum bid price requirement. The company's common stock will trade on a split-adjusted basis from the market opening on April 9, 2024. No fractional shares will be issued; instead, stockholders will receive a rounded up whole share for any fractional share they would have received post-split. Adjustments will also be made to outstanding equity awards, shares issuable under the 2021 equity incentive plan, and the conversion or exercise prices of such awards and plans. Allarity Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing personalized cancer treatments and is currently advancing a phase 2 clinical trial for stenoparib, a novel PARP/Tankyrase inhibitor, using its DRP® companion diagnostic for patient selection.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more